2019 Annual Meeting | C160 - Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience

Date Tuesday 05/07/19

Time 03:30 PM - 05:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eoin P. Flanagan, MBBCh, FAAN

Topic(s) Autoimmune Neurology, Multiple Sclerosis

Learning Objectives Participants should be able to understand the autoantibody nomenclature, recognize autoimmune neurologic disorders occuring in novel settings, know the neurologic and cancer associations of the autoantibodies, know the pitfalls in antibody testing, know the appropriate oncological evaluations for paraneoplastic neurologic disorders, understand how to diagnose and treat autoimmune epilepsy, and know some treatment regimens for autoimmune neurologic disorders.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Program Tracks Neurohospitalist

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM EDT	Introduction	Introduction Eoin P. Flanagan, MBBCh, FAAN
03:35 PM - 04:10 PM EDT	Speaker	Diagnostic Approach to Autoimmune Encephalitis Eoin P. Flanagan, MBBCh, FAAN
04:10 PM - 04:45 PM EDT	Speaker	Autoimmune Epilepsy: From Faciobrachial Dystonic Seizures to Status Epilepticus Sarosh R. Irani, MD, PhD, FRCP, FEAN
04:45 PM - 05:20 PM EDT	Speaker	The Expanding Spectrum of Autoimmune Encephalitis Beyond Paraneoplastic Disease Jenny Linnoila, MD, PhD
05:20 PM - 05:30 PM EDT	Q&A	Questions and Answers and Closing Remarks

Faculty Disclosures
Eoin P. Flanagan, MBBCh, FAAN	The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.
Jenny Linnoila, MD, PhD	Dr. Linnoila has received research support from NIH/NINDS. Dr. Linnoila has received personal compensation in the range of $10,000-$49,999 for serving as a expert respondent on autoimmune encephalitis with U.S. government/DHHS/vaccine injury compensation program.
Sarosh R. Irani, MD, PhD, FRCP, FEAN	Dr. Irani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, Biogen, Amgen, Argenex, Clarivate, IQVIA, BioHaven therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma.. Dr. Irani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. Dr. Irani has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for LLPs. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��